Somatostatin receptor imaging in somatotroph and non-functioning pituitary adenomas: correlation with hormonal and visual responses to octreotide-Reference-Cited by-同舟云学术

Somatostatin receptor imaging in somatotroph and non-functioning pituitary adenomas: correlation with hormonal and visual responses to octreotide

Published:1997-11 Issue:5 Volume:47 Page:589-598
ISSN:0300-0664
Container-title:Clinical Endocrinology
language:en
Short-container-title:Clinical Endocrinology

Author:

Borson-Chazot Françoise,Houzard Claire,Ajzenberg Christiane,Nocaudie Marie,Duet Michèle,Mundler Olivier,Marchandise Xavier,Epelbaum Jacques,Gomez De Alzaga Maria,Schäfer Judith,Meyerhof Wolfgang,Sassolas Geneviève,Warnet André

Publisher

Wiley

Subject

Endocrinology, Diabetes and Metabolism,Endocrinology

Link

http://onlinelibrary.wiley.com/wol1/doi/10.1046/j.1365-2265.1997.3361119.x/fullpdf

Cited by 53 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Lanreotide versus placebo for tumour reduction in patients with a 68Ga-DOTATATE PET-positive, clinically non-functioning pituitary macroadenoma (GALANT study): a randomised, multicentre, phase 3 trial with blinded outcome assessment;The Lancet Regional Health - Europe;2024-07

2. Predictors of biochemical response to somatostatin receptor ligands in acromegaly;Best Practice & Research Clinical Endocrinology & Metabolism;2024-07

3. Predictors of Response to Treatment with First-Generation Somatostatin Receptor Ligands in Patients with Acromegaly;Archives of Medical Research;2023-12

4. Using Molecular Imaging to Enhance Decision Making in the Management of Pituitary Adenomas;Journal of Nuclear Medicine;2021-07

5. The GALANT trial: study protocol of a randomised placebo-controlled trial in patients with a 68Ga-DOTATATE PET-positive, clinically non-functioning pituitary macroadenoma on the effect of lanreotide on tumour size;BMJ Open;2020-08